Prostate-specific membrane antigen - PubMed (original) (raw)
Review
Prostate-specific membrane antigen
W R Fair et al. Prostate. 1997.
Abstract
Background: In an effort to discover new prostate-specific antigens (PSAs) to enhance our understanding of the functions and behavior of the prostate and the complex processes involved in prostate tumor progression, the structure and function of the PSM antigen has been elucidated.
Methods: The PSM antigen was recognized using the 7E11-C5.3 monoclonal antibody, generated against the LNCaP human prostate adenocarcinoma cell line. The PSM cDNA was isolated by PCR, using tryptic peptides of immunoprecipitated PSM to design degenerate primers.
Results: The prostate specific membrane antigen (PSM) is a 100 KD glycoprotein which appears to be a type II integral membrane protein. The protein and cDNA have been extensively characterized and the findings reviewed in the report.
Conclusions: PSM, a new prostate antigen is valuable as a marker for hematogenous micro-metastatic tumor dissemination as detected in RT-PCR assays of peripheral blood. PSM has many properties that may be potentially useful as a molecular target in monoclonal antibody directed strategies of tumor imaging and therapy.
Similar articles
- Expression of the prostate-specific membrane antigen.
Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Israeli RS, et al. Cancer Res. 1994 Apr 1;54(7):1807-11. Cancer Res. 1994. PMID: 7511053 - Prostate-specific membrane antigen: evidence for the existence of a second related human gene.
Leek J, Lench N, Maraj B, Bailey A, Carr IM, Andersen S, Cross J, Whelan P, MacLennan KA, Meredith DM, et al. Leek J, et al. Br J Cancer. 1995 Sep;72(3):583-8. doi: 10.1038/bjc.1995.377. Br J Cancer. 1995. PMID: 7669565 Free PMC article. - Localization and physical mapping of the prostate-specific membrane antigen (PSM) gene to human chromosome 11.
Rinker-Schaeffer CW, Hawkins AL, Su SL, Israeli RS, Griffin CA, Isaacs JT, Heston WD. Rinker-Schaeffer CW, et al. Genomics. 1995 Nov 1;30(1):105-8. doi: 10.1006/geno.1995.0019. Genomics. 1995. PMID: 8595888 - Prostate-specific membrane antigen and other prostatic tumor markers on the horizon.
Israeli RS, Grob M, Fair WR. Israeli RS, et al. Urol Clin North Am. 1997 May;24(2):439-50. doi: 10.1016/s0094-0143(05)70391-8. Urol Clin North Am. 1997. PMID: 9126242 Review. - Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction.
Su SL, Heston WD, Perrotti M, Cookson MS, Stroumbakis N, Huyrk R, Edwards E, Brander B, Coke J, Soloway S, Lewis A, Fair WR. Su SL, et al. Urology. 1997 Mar;49(3A Suppl):95-101. doi: 10.1016/s0090-4295(97)00175-1. Urology. 1997. PMID: 9123743 Review.
Cited by
- Recombinant full-length human IgG1s targeting hormone-refractory prostate cancer.
Liu B, Conrad F, Roth A, Drummond DC, Simko JP, Marks JD. Liu B, et al. J Mol Med (Berl). 2007 Oct;85(10):1113-23. doi: 10.1007/s00109-007-0208-z. Epub 2007 Jun 7. J Mol Med (Berl). 2007. PMID: 17554518 - Transporter and protease mediated delivery of platinum complexes for precision oncology.
Hambley TW. Hambley TW. J Biol Inorg Chem. 2019 Jun;24(4):457-466. doi: 10.1007/s00775-019-01660-7. Epub 2019 May 15. J Biol Inorg Chem. 2019. PMID: 31093745 Review. - Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells.
Liu J, Kopecková P, Bühler P, Wolf P, Pan H, Bauer H, Elsässer-Beile U, Kopecek J. Liu J, et al. Mol Pharm. 2009 May-Jun;6(3):959-70. doi: 10.1021/mp8002682. Mol Pharm. 2009. PMID: 19344119 Free PMC article. - Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer.
Eder M, Neels O, Müller M, Bauder-Wüst U, Remde Y, Schäfer M, Hennrich U, Eisenhut M, Afshar-Oromieh A, Haberkorn U, Kopka K. Eder M, et al. Pharmaceuticals (Basel). 2014 Jun 30;7(7):779-96. doi: 10.3390/ph7070779. Pharmaceuticals (Basel). 2014. PMID: 24983957 Free PMC article. - Evaluating the transcriptional fidelity of cancer models.
Peng D, Gleyzer R, Tai WH, Kumar P, Bian Q, Isaacs B, da Rocha EL, Cai S, DiNapoli K, Huang FW, Cahan P. Peng D, et al. Genome Med. 2021 Apr 29;13(1):73. doi: 10.1186/s13073-021-00888-w. Genome Med. 2021. PMID: 33926541 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous